Latent Class Analysis Identifies Pulmonary Function Trajectory Phenotypes in Lung Transplant Recipients with Chronic Allograft Dysfunction
Background: We aimed to identify data-driven FEV1 trajectory phenotypes post-chronic lung allograft dysfunction (CLAD), relate these phenotypes to patient factors and future graft loss, and develop a classification approach for prospective patients. Methods: We studied adult first lung recipients with probable CLAD from two prospective multicenter cohorts: CTOT-20 (n=206) and LTOG (n=1418). FEV1 trajectories over the first nine months post-CLAD were characterized using joint latent class mixed models, jointly modelling time-to-graft loss to account for informative censoring. Models were fit independently in both cohorts and also only among LTOG bilateral recipients. A classification and regression tree (CART) model was derived in LTOG bilateral recipients and applied to CTOT-20 bilateral recipients. Findings: Four distinct early FEV1 trajectory classes were identified in CTOT-20, with large differences in nine-month graft loss (72·3%, 31·1%, 2·2%, 0%). In LTOG, similar trajectory patterns were reproduced, with an additional class demonstrating early post-CLAD FEV1 improvement. Among bilateral recipients, trajectory classes showed a clear risk gradient, including a high-risk class with 100% graft loss and a low-risk class with no early graft loss. A CART model incorporating clinical and spirometric variables demonstrated good discrimination in LTOG bilateral recipients (multiclass AUC 0·85) and consistent class assignment and trajectory patterns when applied to CTOT-20. Interpretation: We identified reproducible, clinically meaningful early post-CLAD FEV1 trajectory phenotypes with differential graft loss risk. These phenotypes and a pragmatic classification tool may support risk stratification, trial enrichment, and improved prognostication for patients and clinicians. Funding: National Institutes of Health, Cystic Fibrosis Foundation.
Authors
- L. Kalman
- Jesse Y. Hsu (ORCID: https://orcid.org/0000-0002-1522-6534)
- J Belperio
- L. Singer
- P Wang
- Michaela Restivo Anderson (ORCID: https://orcid.org/0000-0001-9274-7643)
- Jason D. Christie (ORCID: https://orcid.org/0000-0003-0519-218X)
- Krishna Pandya (ORCID: https://orcid.org/0000-0001-9035-3181)
- DANIEL M. WOJDYLA (ORCID: https://orcid.org/0009-0009-3431-2014)
- David Roe
- Luke Benvenuto
- John McDyer
- Wayne Tsuang
- Marie Budev
- Jamie Todd
- Scott M Palmer
- Laurie P Snyder
- Michael Combs
- Katelyn Arroyo
- Michelle Oyster
- S. Samuel Weigt
- Gundeep Dhillon
- Jonathan P Singer
- Pali D Shah
- John M Reynolds
- Jeeyon G Rim
- Tereza Martinu
- Hwanhee Hong
- Megan Neely
Institutions
- Indiana University Health (US)
- Cleveland Clinic (US)
- University Health Network (CA)
- NewYork–Presbyterian Hospital (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
- Duke University (US)
- University of California, San Francisco (US)
- University of Toronto (CA)
- University of Michigan (US)
- Columbia University Irving Medical Center (US)
- California University of Pennsylvania (US)
- Clinical Research Institute (US)
- Stanford Health Care (US)
- Michigan Medicine (US)
- Duke Medical Center (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-04-23
- DOI
- https://doi.org/10.64898/2026.04.22.26351501
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cystic Fibrosis Foundation
- Sanofi
- CareDx
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases